APA (7th ed.) Citation

B, M., KV, H., AR, H., AM, O., P, N., F, K., . . . JE, L. (2023). Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: A phase 1, open-label, dose-escalation clinical trial. The Lancet. Infectious diseases, 23(12), 1408. https://doi.org/10.1016/S1473-3099(23)00344-4

Chicago Style (17th ed.) Citation

B, Mwesigwa, et al. "Safety, Tolerability, and Immunogenicity of the Ebola Sudan Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO S) in Healthy Ugandan Adults: A Phase 1, Open-label, Dose-escalation Clinical Trial." The Lancet. Infectious Diseases 23, no. 12 (2023): 1408. https://doi.org/10.1016/S1473-3099(23)00344-4.

MLA (9th ed.) Citation

B, Mwesigwa, et al. "Safety, Tolerability, and Immunogenicity of the Ebola Sudan Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO S) in Healthy Ugandan Adults: A Phase 1, Open-label, Dose-escalation Clinical Trial." The Lancet. Infectious Diseases, vol. 23, no. 12, 2023, p. 1408, https://doi.org/10.1016/S1473-3099(23)00344-4.